Back to Journals » Therapeutics and Clinical Risk Management » Volume 16

Safety Profile of Musculoskeletal Contrast-Enhanced Ultrasound with Sulfur Hexafluoride Contrast Agent

Authors Fischer C, Kunz P, Strauch M, Weber MA, Doll J

Received 18 October 2019

Accepted for publication 9 March 2020

Published 14 April 2020 Volume 2020:16 Pages 269—280


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Christian Fischer,1,* Pierre Kunz,1,* Marten Strauch,1 Marc-André Weber,2 Julian Doll1

1Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, Ultrasound Center, HTRG - Heidelberg Trauma Research Group, Heidelberg University Hospital, Heidelberg 69118, Germany; 2Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medical Center Rostock, Rostock 18057, Germany

*These authors contributed equally to this work

Correspondence: Julian Doll
Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, Ultrasound Center HTRG – Heidelberg Trauma Research Group Heidelberg University Hospital, Schlierbacher Landstrasse 200a, Heidelberg 69118, Germany
Tel +49 6221 5636388
Fax +49 6221 5629213
Email [email protected]

Purpose: Muscle, bone and tendon regeneration depend on the microperfusion of the corresponding tissue which can be quantified with contrast-enhanced ultrasound (CEUS) using sulfur hexafluoride contrast agent (SonoVue®). This study investigated the incidence of adverse events (AEs) in musculoskeletal patients and gives an overview of musculoskeletal CEUS applications.
Patients and Methods: Based on 13 studies in a standardized monocentric setting, a total of 2268 CEUS examinations in 764 patients were performed and AEs due to the administration of sulfur hexafluoride contrast agent were classified as either mild, moderate or severe.
Results: No fatal events occurred. AEs were reported in three cases, of which only one was classified as severe and two as mild. The total rate of all AEs was 0.13% and 0.04% for severe AEs.
Conclusion: The present analysis confirms the safety of musculoskeletal CEUS using sulfur hexafluoride contrast agent with a lower rate of AEs than that reported for other contrast agents even in elderly patients with concomitant diseases.

Keywords: contrast-enhanced ultrasound, CEUS, sulfur hexafluoride, musculoskeletal, contrast agents, adverse events

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]